Drug Profile
Imatinib - Exvastat
Alternative Names: Imatinib Mesylate - Exvastat; Impentri®Latest Information Update: 05 Feb 2023
Price :
$50 *
At a glance
- Originator Exvastat
- Class Amines; Anti-inflammatories; Antineoplastics; Antivirals; Benzamides; Eye disorder therapies; Piperazines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Bcr-Abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists; Proto-oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Adult respiratory distress syndrome; SARS-CoV-2 acute respiratory disease
- No development reported Acute lung injury
Most Recent Events
- 04 Sep 2022 Efficacy and adverse events data from phase II INVENT-COVID trial in SARS-COV-2 acute respiratory disease presented at the 32nd Annual Congress of the European Respiratory Society (ERS-2022)
- 28 Jul 2022 Exvastat withdraws the phase II IMPRESS COVID trial prior to enrolment in Adult respiratory distress syndrome in India (IV, Infusion) as the number of moderate to severe ARDS patients hospitalised due to COVID-19 was diminishingly small, not expected to recruit required minimum number of patients (NCT04953052)
- 07 Apr 2022 Exvastat terminates phase II trial in SARS-COV-2 acute respiratory disease in Netherlands (IV) due to the decline of COVID-19 patients on Dutch ICUs (NCT04794088; EudraCT2020-005447-23)